China Adrenal Disease Registry Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 2,000
- 试验地点
- 1
- 主要终点
- Percentage of adrenal diseases in China
研究概览
简要总结
Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide. In order to meet all the therapeutic challenges in adrenal disease in China, CASE was founded in 2020. The objective of CASE is to launch an adrenal disease management model based on the Internet health information platform which allows the application and evaluation of adrenal disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of adrenal disease, diagnosis, and treatment.
详细描述
In order to meet all the challenges in the diagnosis and treatment of adrenal diseases in China, CASE was founded in 2020. With advanced medical equipment and Internet of Things (IoT) technology, CASE is committed to creating an online and offline integrated solution for adrenal disease, and for the entire spectrum of adrenal disease, to achieve a more convenient and precise model of care for patients, aiming to establish a platform with diagnosis and treatment of adrenal disease and their long-term follow-up. It allows the application and evaluation of treatment strategies at these centers.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 16 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 16 years old and ≤ 75 years
- •Patients diagnosed with adrenal associated diseases, including cushing syndrome, primary aldosteronism, primary hypoadrenalism, congenital adrenal hyperplasia and adrenal adenomas, incidentalomas, and carcinomas, pheochromocytoma, etc.
- •Provide written informed consent
- •Satisfactory compliance
排除标准
- •Patients with significantly reduced life expectancy (less than 2 years)
- •With Drug abuse
- •With AIDS or syphilis or infectious diseases such as viral tuberculosis in active phase at enrollment
结局指标
主要结局
Percentage of adrenal diseases in China
时间窗: through study completion, an average of 1 year
Number of participants with complication of adrenal diseases in China
时间窗: through study completion, an average of 1 year
次要结局
- concentration of adrenocorticotropic hormone(through study completion, an average of 1 year)
- concentration of 17-hydroxyprogesterone(through study completion, an average of 1 year)
- concentration of cortisol(through study completion, an average of 1 year)
- changes in adrenal CT(through study completion, an average of 1 year)
- percentage of hypoadrenalism(through study completion, an average of 1 year)
- concentration of metanephrines(through study completion, an average of 1 year)
- Mental health status(through study completion, an average of 1 year)
- concentration of aldosterone(through study completion, an average of 1 year)
- concentration of urine cortisol(through study completion, an average of 1 year)
- concentration of androstenedione(through study completion, an average of 1 year)
研究者
Wang Weiqing
Director, Head of Endocrinology, Principal Investigator, Clinical Professor
Shanghai Jiao Tong University School of Medicine